Study Type Number of patients Clinical Response Survival outcomes Pagano et al.[19] Retrospective registry 43 AML induction regimen*CR 27%, PR 19%, relapse 0% ALLinduction regimen**CR 67%, PR 7%, relapse 60% AML regimen: Median OS 7.1 monthsALL regimen: Median OS 12.3 months Tsagarakis et al.[21] Retrospectiveregistry 20 AML induction regimen†CR1 50%, relapse 33%ALL induction regimen‡CR1 100%, relapse 33% OS (2-yr) 43%, with 33% of AML regimen patients and 67% of ALL regimen patientsalive. Dalle et al. [22] Retrospectiveregistry 9 CHOP regimenCR in 56% of patients treated Median OS 11 months and median RFS 7 months Heinicke et al.[15] Retrospectivesingle centre 5 CHOP regimenNot reported Median OS 9 months

Note: OS: overall survival, CR: complete remission, CR1: first complete remission, CR2: second complete remission, PR: partial remission, RFS: relapse-free survival,AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, *AML induction regimen included MICE (mitoxatrone, cytarabine, etoposide), ICE (idarubicin, cytarabine, etoposide), anthracycline+cytarabine 3+7, FLAG (fludarabine,cytarabine, filgastrim), FLAG-IDA (FLAG+idarubicin). **ALL induction regimens included hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), GIMEMA ALL (doxorubicin, vincristine,prednisone, asparaginase), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CHOEP (CHOP+etoposide). †AML induction regimen included cytarabine, fludarabine, idarubicin, vincristine, etoposide, mitoxantrone, prednisolone, dexamethasone. ‡ALL induction regimens included hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), MRC UKALL XII (daunorubicin, vincristine,asparaginase, prednisolone, methotrexate, cyclophosphamide, cytarabine, 6-mercaptopurine), POMP (6-mercaptopurine, vincristine, methotrexate, prednisolone).

Table 1: Selected published data evaluating induction chemotherapy in blastic plasmacytoid dendritic cell neoplasm.